The pharmaceutical company Ferrer, a CataloniaBio & HealthTech  member, will invest 20 million euros in converting its dermocosmetics plant in Esplugues de Llobregat so that it can also produce liquid medicines.

In an interview with the EFE news agency, Mario Rovirosa, CEO of Ferrer, explained that the company wants to further promote the brand's drugs, its  own innovation and focus on therapeutic areas such as neurology and pneumology. These are actions that Ferrer had stablished in his strategic plan until 2025, which has now been ratified and extended for the period 2022-2026.

The changes  at the Esplugues dermocosmetics plant is one of the company’s ongoing projects; the works began in 2020 and are expected to be completed in 2023. With part of the production of liquid drugs in the Baix Llobregat, Ferrer plans to gain space in the Sant Cugat plant to focus on the production of solid drugs.

Ferrer earns 56% of his income abroad and wants to boost the weight of international business. Rovirosa points out that at the end of the strategic plan, sales  outside Spain should have increased around 75%. The laboratories plan to launch new products between 2023 and 2026 and are studying opening new branches in the coming years in countries where they still are not present, such as Italy, France, and the United Kingdom, also strengthening the presence in Germany.